Search
for
Sort by
Research 31–60 of 1000+
- Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib
- Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
- Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
- Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
- Clinical and demographic factors associated with nail involvement in adult alopecia areata patients at Al-Kadhmia teaching hospital, Baghdad, 2023
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
- 93 Approach to Managing Recalcitrant Alopecia Areata With Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study
- Effects of Topical Cyclosporin-A in the Treatment of Alopecia Areata
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
- Alopecia areata: Time for position statement to include new systemic therapeutic advances
- Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients with Clinically Distinct Alopecia Areata Severity Profiles
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
- Combination of photodynamic therapy with 5‐aminolaevulinic acid and microneedling in the treatment of alopecia areata resistant to conventional therapies: our experience with 41 patients
- Janus kinase inhibitors: An innovative treatment for alopecia areata
- Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
- Novel investigational drugs for alopecia areata and future perspectives
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double‐blind placebo‐controlled trial
- JAK Inhibitors for Treatment of Alopecia Areata
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
- A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization of severity and associated treatment utilization
- Assessment of the Mean Platelet Volume-to-Platelet Count Ratio in Alopecia Areata: A Retrospective Case Control Study